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AbstrAct
Objective
To determine the clinical manifestations, risk factors, 
and maternal and perinatal outcomes in pregnant and 
recently pregnant women with suspected or confirmed 
coronavirus disease 2019 (covid-19).
Design
Living systematic review and meta-analysis.
Data sOurces
Medline, Embase, Cochrane database, WHO COVID-19 
database, China National Knowledge Infrastructure 
(CNKI), and Wanfang databases from 1 December 
2019 to 26 June 2020, along with preprint servers, 
social media, and reference lists.
stuDy selectiOn
Cohort studies reporting the rates, clinical 
manifestations (symptoms, laboratory and 
radiological findings), risk factors, and maternal and 
perinatal outcomes in pregnant and recently pregnant 
women with suspected or confirmed covid-19.
Data extractiOn
At least two researchers independently extracted the 
data and assessed study quality. Random effects 
meta-analysis was performed, with estimates pooled 
as odds ratios and proportions with 95% confidence 
intervals. All analyses will be updated regularly.
results
77 studies were included. Overall, 10% (95% 
confidence interval 7% to14%; 28 studies, 11 432 
women) of pregnant and recently pregnant women 
attending or admitted to hospital for any reason 
were diagnosed as having suspected or confirmed 
covid-19. The most common clinical manifestations 
of covid-19 in pregnancy were fever (40%) and 
cough (39%). Compared with non-pregnant women 
of reproductive age, pregnant and recently pregnant 
women with covid-19 were less likely to report 
symptoms of fever (odds ratio 0.43, 95% confidence 
interval 0.22 to 0.85; I2=74%; 5 studies; 80 521 
women) and myalgia (0.48, 0.45 to 0.51; I2=0%; 3 
studies; 80 409 women) and were more likely to need 
admission to an intensive care unit (1.62, 1.33 to 
1.96; I2=0%) and invasive ventilation (1.88, 1.36 to 
2.60; I2=0%; 4 studies, 91 606 women). 73 pregnant 
women (0.1%, 26 studies, 11 580 women) with 
confirmed covid-19 died from any cause. Increased 
maternal age (1.78, 1.25 to 2.55; I2=9%; 4 studies; 
1058 women), high body mass index (2.38, 1.67 
to 3.39; I2=0%; 3 studies; 877 women), chronic 
hypertension (2.0, 1.14 to 3.48; I2=0%; 2 studies; 
858 women), and pre-existing diabetes (2.51, 1.31 to 
4.80; I2=12%; 2 studies; 858 women) were associated 
with severe covid-19 in pregnancy. Pre-existing 
maternal comorbidity was a risk factor for admission 
to an intensive care unit (4.21, 1.06 to 16.72; I2=0%; 
2 studies; 320 women) and invasive ventilation 
(4.48, 1.40 to 14.37; I2=0%; 2 studies; 313 women). 
Spontaneous preterm birth rate was 6% (95% 
confidence interval 3% to 9%; I2=55%; 10 studies; 
870 women) in women with covid-19. The odds of any 
preterm birth (3.01, 95% confidence interval 1.16 
to 7.85; I2=1%; 2 studies; 339 women) was high in 
pregnant women with covid-19 compared with those 
without the disease. A quarter of all neonates born to 
mothers with covid-19 were admitted to the neonatal 
unit (25%) and were at increased risk of admission 
(odds ratio 3.13, 95% confidence interval 2.05 to 
4.78, I2=not estimable; 1 study, 1121 neonates)  
than those born to mothers without covid-19.
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WhAt is AlreAdy knoWn on this topic
Pregnant women are considered to be a high risk group for severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential 
adverse effects of the virus on maternal and perinatal outcomes are of concern
In non-pregnant populations admitted to hospital with coronavirus disease 
2019 (covid-19) the most common symptoms are fever, cough, and dyspnoea, 
reported in more than two thirds of individuals
Advancing age, high body mass index, non-white ethnicity, and pre-existing 
comorbidities are risk factors for severe covid-19 in the general population
WhAt this study Adds
Pregnant and recently pregnant women with covid-19 diagnosed in hospital are 
less likely to manifest symptoms of fever and myalgia than non-pregnant women 
of reproductive age and might be at increased risk of admission to an intensive 
care unit
Risk factors for severe covid-19 in pregnancy include increasing maternal age, 
high body mass index, and pre-existing comorbidities
Pregnant women with covid-19 are more likely to experience preterm birth and 
their neonates are more likely to be admitted to a neonatal unit
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cOnclusiOn
Pregnant and recently pregnant women are less likely 
to manifest covid-19 related symptoms of fever and 
myalgia than non-pregnant women of reproductive 
age and are potentially more likely to need 
intensive care treatment for covid-19. Pre-existing 
comorbidities, high maternal age, and high body mass 
index seem to be risk factors for severe covid-19. 
Preterm birth rates are high in pregnant women with 
covid-19 than in pregnant women without the disease.
systematic review registratiOn
PROSPERO CRD42020178076.
reaDers’ nOte
This article is a living systematic review that will be 
updated to reflect emerging evidence. Updates may 
occur for up to two years from the date of original 
publication.
introduction
Since the first report (December 2019) of the novel 
coronavirus disease 2019 (covid-19) caused by 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), the number of confirmed cases and 
associated mortality and morbidity have increased 
rapidly.1 2 Pregnant women are considered a high 
risk group because of concerns about the effect of 
covid-19 on them during and after pregnancy, and 
on their neonates.3 Quantification of the rates of 
covid-19, its risk factors, clinical manifestations, and 
outcomes is key to planning clinical maternal care and 
management in an evolving pandemic scenario.4
Publications on covid-19 in pregnancy have risen 
steeply through individual case reports, case series, 
observational studies, and systematic reviews. 
As of 26 June 2020, more than 86 reviews have 
been published in this area,5-10 with a further 94 
registered in PROSPERO.8 11 The early reviews mostly 
included case reports and case series that were often 
inappropriately meta-analysed, leading to biased 
estimates.12 Subsequent reviews differed little from 
each other, often including similar primary studies, 
many with duplicate data. These reviews became 
quickly outdated as new evidence emerged. To 
date, no review has comprehensively evaluated the 
comparative data concerning pregnant and recently 
pregnant women and non-pregnant women with 
covid-19. Moreover, the sampling frames in primary 
studies have varied, ranging from universal SARS-
CoV-2 testing for all pregnant women admitted to 
hospital13 14 to symptom based testing.15 16 Testing 
strategies have also differed within and between 
countries, with diagnosis in many early studies based 
on epidemiological risk assessment and clinical 
features without confirmed infection, which need to be 
considered in the analysis.17 Limitations in the external 
and internal validity of studies make it challenging 
for guideline developers and policy makers to make 
evidence based recommendations for the management 
of pregnant and recently pregnant women with 
covid-19.
We began a living systematic review to determine 
the clinical manifestations of covid-19 in pregnant and 
recently pregnant women, identify the risk factors for 
complications, and quantify maternal and perinatal 
outcomes. This systematic review will be updated on 
a regular basis.
Methods
Our systematic review is based on a prospectively 
registered protocol (PROSPERO CRD42020178076; 
registered 22 April 2020)18 to evaluate a series of 
research questions on covid-19 during and after 
pregnancy. We report our findings on the rates, 
clinical manifestations, risk factors, and maternal and 
perinatal outcomes in women with covid-19 in line with 
the preferred reporting items for systematic reviews 
and meta-analyses (PRISMA) recommendations 
(see appendix 1). As more relevant data become 
available, we shall address the research questions 
in our published protocol. Each cycle of our living 
systematic review involves weekly search updates 
(rounds), with analysis performed every 2-4 weeks for 
our monthly reporting through a dedicated website, 
with early analysis if new definitive evidence emerges. 
We plan to regularly review the planned frequency of 
updates.
literature search
We performed a systematic search of major databases: 
Medline, Embase, Cochrane database, WHO (World 
Health Organization) COVID-19 database, China 
National Knowledge Infrastructure (CNKI), and 
Wanfang databases from 1 December 2019 to 26 June 
2020 for relevant studies on covid-19 in pregnant and 
recently pregnant women. To identify potential studies, 
we coordinated our search efforts with the Evidence 
for Policy and Practice Information and Co-ordinating 
Centre (EPPI-Centre), the WHO Library, and the 
Cochrane Gynaecology and Fertility group. Additional 
searches were conducted of preprint servers, blogs, 
websites that serve as repositories for covid-19 studies, 
social media, guidelines, and reference lists of included 
studies and unpublished data. We also searched the 
Living Overview of the Evidence (LOVE) platform from 
11 to 26 June 2020.19 We contacted established groups 
that were coordinating or conducting surveillance and 
studies in pregnant women with covid-19, such as 
the WHO Maternal, Newborn, Child and Adolescent 
health (MNCAH) covid-19 research network and the 
International Network of Obstetric Survey Systems 
(INOSS) for information on published and upcoming 
data. No language restrictions were applied. Appendix 
2 provides details of the search strategies and 
databases searched.
study selection
Two reviewers independently selected studies using 
a two stage process: they first screened the titles and 
abstracts of studies and then assessed the full text 
of the selected studies in detail for eligibility. A total 
of eight reviewers contributed to study selection. 
copyright.
 o
n
 11 Septem
ber 2020 at St G
eorge's, University of London. Protected by
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m3320 on 1 September 2020. Downloaded from 
RESEARCH
the bmj | BMJ 2020;370:m3320 | doi: 10.1136/bmj.m3320 3
Disagreements were resolved through discussion 
with a third reviewer (ST or JA). We excluded studies 
if the duplicate data for all outcomes of interest were 
published elsewhere, as reported by the study authors, 
or when the characteristics of the mother or neonate 
matched the setting, characteristics, and duration of 
another study. When we suspected an overlap of data 
between studies, the study that provided comparative 
data was included. When there was uncertainty about 
duplicate data, we contacted the authors of primary 
studies.
We defined women as having confirmed covid-19 
if they had laboratory confirmation of covid-19 
infection irrespective of clinical signs and symptoms.20 
Women with a diagnosis based only on clinical or 
radiological findings were defined as having suspected 
covid-19. The recently pregnant group comprised 
women in the postpartum and post-abortion period. 
We included studies that compared covid-19 rates, 
clinical manifestations (symptoms, laboratory and 
radiological results), risk factors, and associated 
mortality and morbidity between pregnant and 
recently pregnant and non-pregnant women of 
reproductive age, and those that compared maternal 
and perinatal outcomes in pregnant women with and 
without covid-19. Studies on non-comparative cohorts 
with a minimum of 10 participants were included if 
they reported on the rates and clinical manifestations 
of covid-19 and relevant outcomes in pregnant and 
recently pregnant women. We defined cohort studies 
as those that sampled participants on the basis of 
exposure, followed-up participants over time, and 
ascertained the outcomes.21 The PROSPERO protocol 
provides a full list of the risk factors, clinical features, 
and outcomes evaluated.18
The sampling frames for detecting covid-19 included 
universal screening and testing, when all women were 
assessed for covid-19 using reverse transcriptase 
polymerase chain reaction (RT-PCR) for SARS-CoV-2 
or chest computed tomography; risk based testing 
on the basis of epidemiological history and clinical 
manifestations by National Health Commission of 
China (NHCC) guidelines17; and symptom based when 
testing was performed on women with symptoms and 
those with a history of contact with affected individuals. 
We defined the population as being selected when 
only specific groups of women were included, such 
as those undergoing caesarean section or in the third 
trimester. We categorised studies as a high risk group if 
only women with any pre-existing medical or obstetric 
risk factors were included, low risk if women did not 
have any risk factors, and any risk if all women were 
included.
study quality assessment and data extraction
The quality of the comparative cohort studies was 
assessed for selection, comparability, and outcome 
ascertainment bias using the Newcastle Ottawa 
scale.22 Studies achieving four stars for selection, two 
for comparability, and three for ascertainment of the 
outcome were considered to have a low risk of bias. 
Studies achieving two or three stars for selection, one 
for comparability, and two for outcome ascertainment 
were considered to have a medium risk of bias, 
and any study achieving one star for selection or 
outcome ascertainment, or zero for any of the three 
domains, was regarded as having a high risk of bias. 
We assessed the quality of studies reporting on the 
prevalence of clinical manifestations or outcomes 
for internal and external validity using an existing 
tool.23 The following were considered as low risk of 
bias for external validity: representative of national 
population for relevant variables (population), 
representative of target population (sampling frame), 
random selection (selection bias), and more than 
75% response rate in individuals with and without 
the outcome (non-response bias).23 Two indepen-
dent reviewers extracted data using a pre-piloted 
form.
statistical analysis
We pooled the comparative dichotomous data using 
random effects meta-analysis and summarised 
the findings as odds ratios with 95% confidence 
intervals. To combine comparative continuous data 
with dichotomous data we transformed standardised 
mean differences to logarithm odds ratios, assuming 
a normal underlying distribution.24 We pooled the 
dichotomous non-comparative data for rates of clinical 
manifestations and maternal and perinatal outcomes 
as proportions with 95% confidence intervals using 
Dersimonian and Laird random effects meta-analysis 
after transforming data using Freeman-Tukey double 
arcsin transformation. Heterogeneity was reported 
as I2 statistics. We undertook subgroup analysis by 
country status (high versus low and middle income), 
sampling frame (universal, risk based, and symptom 
based testing, including not reported), and risk status 
of women in the studies (high, low, any). Sensitivity 
analysis was performed by restricting the analysis 
to women with confirmed covid-19, study quality 
(high, low), and population (unselected, selected). All 
analyses were done with Stata (version 16).
Patient and public involvement
The study was supported by Katie’s Team, a dedicated 
patients and public involvement group in Women’s 
Health. The team was involved in the conduct, 
interpretation, and reporting of this living systematic 
review through participation in virtual meetings.
results
After removing duplicates from 49 684 citations, 
20 625 unique citations were identified and 77 cohort 
studies (55 comparative, 22 non-comparative) were 
included in the systematic review (fig 1).
characteristics of included studies
Of the 77 studies, 26 (34%) were from the United States, 
24 from China (31%), seven from Italy, six from Spain, 
three each from the United Kingdom and France, and 
one each from Belgium, Brazil, Denmark, Israel, Japan, 
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Mexico, the Netherlands, and Portugal. All the studies 
tested respiratory samples using RT-PCR to confirm 
the presence of SARS-CoV-2; 23 studies additionally 
diagnosed covid-19 based on clinical suspicion. 
Eight studies (95 247 women) compared pregnant 
populations with non-pregnant populations,25-32 
and four studies (2230 women) compared pregnant 
women with covid-19 versus pregnant women 
without covid-19.33-36 Forty cohort studies reported 
on clinical manifestations (13 018 pregnant, 85 084 
non-pregnant women),25-32 35-66 45 studies reported on 
covid-19 related maternal outcomes (14 094 pregnant, 
85 169 non-pregnant women),25-32 35-51 53-59 61-74 and 
35 studies reported on pregnancy related maternal 
(6279 women) and perinatal outcomes (2557 
neonates)13 25 27 29 30 32-41 43-47 49-50 54 55 57 59 61 62 64-67 69 70 75 
(see appendix 3). The sampling frames included 
universal testing (29 studies), risk based NHCC 
guidelines (22 studies), and symptom based (19 
studies) strategies. Eleven studies did not report the 
sampling strategy.
Quality of included studies
Overall, 67% (37/55) of the comparative cohort 
studies evaluated using the Newcastle Ottawa scale 
had an overall low risk of bias (see appendix 4a). Forty 
nine (89%) had a low risk of bias for study selection 
and six (11%) had a medium risk. The risk of bias for 
comparability of cohorts was low in nine of the studies 
(16%), medium in 45 (82%), and high in one (2%). For 
outcome assessment of the cohorts, 12 (22%) studies 
had a low risk of bias, 42 (76%) a medium risk, and one 
(2%) a high risk. Quality assessment of the prevalence 
studies for external validity showed a low risk of bias 
for representativeness in 13% (10/76) of the studies, 
sampling in 26% (20/76), selection in 74% (56/76), 
and non-response in 96% (73/76). For internal validity, 
there was low risk of bias for data collection in 95% 
(72/76) of the studies, case definition in 36% (27/76), 
measurement in 99% (75/76), differential verification 
in 86% (65/76), adequate follow-up in 22% (17/76), 
and appropriate numerator and denominator in 83% 
(63/76) (see appendix 4b).
Articles excluded
Irrelevant articles
Duplicates
19 460
29 059
Full text articles assessed for eligibility
Citations identified
1165
49 684
48 519
Articles excluded
Inappropriate population
Inappropriate study design
Duplicate publication
Inappropriate outcome
Inappropriate exposure
Article not found
457
452
125
35
18
1
Electronic databases from inception to 26 June 2020
Other sources* and reference lists
49 538
146
Studies included (13 118 pregnant and recently pregnant women with covid-19;
83 486 non-pregnant women of reproductive age with covid-19)
Prevalence of covid-19
Risk factors for covid-19 and complications
Clinical manifestations of covid-19
Covid-19 related outcomes
Pregnancy related maternal and perinatal outcomes
26
52
40
45
35
1088
77
Fig 1 | study selection process. *twitter, national reports, blog by j thornton, Obg Project, cOviD-19 and 
Pregnancy cases, www.obgproject.com/2020/04/07/covid-19-research-watch-with-dr-jim-thornton/ (accessed 
12 may 2020); ePPi-centre, cOviD-19: a living systematic map of evidence, http://eppi.ioe.ac.uk/cms/Projects/
DepartmentofHealthandsocialcare/Publishedreviews/cOviD-19livingsystematicmapoftheevidence/tabid/3765/
Default.aspx (accessed 12 may 2020); norwegian institute of Public Health, niPH systematic and living map 
on cOviD-19 evidence, www.nornesk.no/forskningskart/niPH_mainmap.html (accessed 19 may 2020); johns 
Hopkins university center for Humanitarian Health; cOviD-19, maternal and child Health, nutrition, http://
hopkinshumanitarianhealth.org/empower/advocacy/covid-19/covid-19-children-and-nutrition/ (accessed 2 june 
2020); researchgate, cOviD-19 research community, www.researchgate.net/community/cOviD-19 (accessed 2 
june 2020); and living Overview of the evidence, coronavirus disease (cOviD-19), https://app.iloveevidence.com/
loves/5e6fdb9669c00e4ac072701d?population=5d062d5fc80dd41e58ba8459 (accessed 16 june 2020)
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rates of covid-19 in pregnant and recently pregnant 
women
The overall rate of covid-19 diagnosis in pregnant 
and recently pregnant women attending or admitted 
to hospital for any reason was 10% (95% confidence 
interval 7% to 14%; 26 studies, 11 432 women; fig 
2). Rates varied by sampling strategy: of the women 
sampled by universal screening, 7% (4% to 10%; 
18 studies, 6247 women) were diagnosed as having 
covid-19 compared with 18% (10% to 28%; 8 studies, 
4928 women) of women sampled on the basis of 
symptoms. All studies with a prevalence rate for 
covid-19 greater than 15% were from the US, except 
for one study, which was from France.76 One in 20 
asymptomatic mothers (5%, 2% to 9%; 11 studies) 
attending or admitted to hospital had a diagnosis of 
covid-19 (see appendix 5a). Three quarters (74%, 51% 
to 93%; 11 studies) of the 162 pregnant women with 
covid-19 in the universal screening population were 
asymptomatic (see appendix 5b). Based on data from 
a small number of studies, a diagnosis of covid-19 in 
pregnancy was associated with maternal obesity (odds 
ratio 1.75, 95% confidence interval 1.34 to 2.30; 
1 study, 1080 women), pre-existing comorbidities 
(1.64, 1.25 to 2.13; 1 study, 1121 women), asthma 
(1.71, 1.03 to 2.84; 2 studies, 1250 women), history 
of covid-19 in the support person (44.56, 14.90 to 
133.28; 1 study, 199 women), and gestational diabetes 
(2.42, 1.55 to 3.79; 1 study, 1121 women) (see 
appendix 6a).
Universal screening
  Sutton 2020
  Vintzileos 2020
  Tassis 2020
  Khalil 2020
  Gagliardi 2020
  Naqvi 2020
  Ceulemans 2020
  Miller 2020
  Doria 2020
  London 2020
  Bianco 2020
  Goldfarb 2020
  LaCourse 2020
  Ochiai 2020
  Freiesleben 2020
  Cosma 2020
  Crovetto 2020
  Emeruwa 2020
Subtotal: P=0.00; I2=95.1%
Symptom based screening
  Blitz 2020
  Campbell 2020
  Fox 2020
  Qadri 2020
  Duffy 2020
  London 2020
  LaCourse 2020
  Griffin 2020
Subtotal: P=0.00; I2=97.9%
Not known
  Cohen
Overall: I2=96.99%, P=0.00;
  estimated predictive interval
0.15 (0.11 to 0.21)
0.20 (0.14 to 0.27)
0.02 (0.01 to 0.06)
0.07 (0.04 to 0.13)
0.01 (0.00 to 0.02)
0.01 (0.00 to 0.07)
0.03 (0.02 to 0.05)
0.04 (0.02 to 0.05)
0.12 (0.07 to 0.19)
0.13 (0.07 to 0.23)
0.15 (0.10 to 0.22)
0.03 (0.02 to 0.04)
0.03 (0.01 to 0.06)
0.04 (0.01 to 0.13)
0.03 (0.02 to 0.04)
0.10 (0.07 to 0.15)
0.14 (0.12 to 0.17)
0.18 (0.14 to 0.22)
0.07 (0.04 to 0.10)
0.03 (0.02 to 0.03)
0.04 (0.03 to 0.06)
0.04 (0.03 to 0.06)
0.08 (0.05 to 0.13)
0.41 (0.26 to 0.57)
0.72 (0.61 to 0.80)
0.19 (0.10 to 0.33)
0.33 (0.24 to 0.44)
0.18 (0.10 to 0.28)
0.45 (0.39 to 0.52)
0.10 (0.07 to 0.14);
(0.00 to 0.35)
0 0.803
Study Rate
(95% CI)
Rate
(95% CI)
1
1
2
2
3
3
3
3
3
3
3
4
4
4
5
5
5
5
2
3
3
3
3
3
4
5
5
Round
33/215
32/161
3/139
9/129
3/533
1/82
13/470
23/635
12/103
10/75
24/158
20/757
5/188
2/52
30/1055
23/225
125/874
71/396
82/2971
30/770
33/757
16/192
15/37
58/81
8/42
26/78
88/194
Events/
No in group
Fig 2 | Prevalence of severe acute respiratory syndrome coronavirus 2 in pregnant and recently pregnant women 
identified by various sampling strategies. meta-analysis includes one study (liao 2020) screened using national 
Health commission china criteria with no events. symptom based screening includes screening based on symptoms 
or history of contact with individuals with covid-19. round number represents search strategy updates in the living 
systematic review
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clinical manifestations of covid-19 during 
pregnancy and after delivery
The most common symptoms reported by pregnant 
and recently pregnant women with suspected or 
confirmed covid-19 were fever (40%) and cough 
(39%); lymphopaenia (35%) and raised C reactive 
protein levels (49%) were the most common laboratory 
findings (fig 3). Compared with non-pregnant women 
of reproductive age with covid-19, pregnant and 
recently pregnant women with the disease were 
less likely to manifest symptoms of fever (0.43, 0.22 
to 0.85; 5 studies, 80 521 women) and myalgia 
(0.48, 0.45 to 0.51; 3 studies, 80 409 women) (fig 
4). A history of pre-existing diabetes was more often 
observed in pregnant women with covid-19 than in 
non-pregnant women with the disease (1.78, 1.03 to 
3.05; 3 studies, 91 595 women) (see appendix 6b). 
Sensitivity analysis restricted to various sampling 
frames showed lower estimates of fever, cough, and 
dyspnoea in the universal screening population and 
higher estimates in the symptom based population 
(see appendix 7). The rates of clinical manifestations 
were similar to the overall estimates when the analysis 
was restricted to only women with RT-PCR confirmed 
covid-19, unselected populations, and women with 
any risk (see appendix 7).
Outcomes related to covid-19 in pregnant and 
recently pregnant women
Overall, 73 pregnant women (26 studies, 11 580 
women) with confirmed covid-19 died from any cause 
(0.1%, 95% confidence interval 0.0% to 0.7%). Severe 
covid-19 was diagnosed in 13% (6% to 21%; 21 studies, 
2271 women) of pregnant and recently pregnant 
women with suspected or confirmed covid-19; 4% 
(2% to 7%; 17 studies, 10 901 women) of the pregnant 
women with covid-19 were admitted to an intensive 
care unit, 3% (1% to 5%; 13 studies, 10 713 women) 
required invasive ventilation, and 0.4% (0.1% to 
0.9%; 9 studies, 1935 women) required extracorporeal 
membrane oxygenation (fig 3). Appendix 8 provides the 
rates of complications by sampling strategy. Compared 
with non-pregnant women of reproductive age with 
covid-19, the odds of admission to the intensive care 
unit (1.62, 95% confidence interval 1.33 to 1.96) and 
need for invasive ventilation (1.88, 1.36 to 2.60) were 
higher in pregnant and recently pregnant women (four 
studies, 91 606 women) (table 1). Maternal risk factors 
associated with severe covid-19 were increasing age 
(1.78, 1.25 to 2.55; 4 studies, 1058 women), high 
body mass index (2.38, 1.67 to 3.39; 3 studies, 877 
women), chronic hypertension (2.0, 1.14 to 3.48; 
2 studies, 858 women), and pre-existing diabetes 
(2.51, 1.31 to 4.80; 2 studies, 858 women) (fig 5). 
Pre-existing maternal comorbidity was associated 
with admission to an intensive care unit (4.21, 1.06 to 
16.72; 2 studies, 320 women) and the need for invasive 
ventilation (4.48, 1.40 to 14.37; 2 studies, 313 women) 
(table 2).
maternal and perinatal outcomes in pregnant and 
recently pregnant women with covid-19
In pregnant and recently pregnant women with 
covid-19 the rate of overall preterm birth was 17% 
(95% confidence interval 13% to 21%; 30 studies, 
1872 women) and of spontaneous preterm birth was 
6% (3% to 9%; 10 studies, 870 women) (fig 3). In 
pregnant and recently pregnant women with covid-19 
compared with pregnant and recently pregnant 
women without the disease, the odds of any preterm 
birth (3.0, 95% confidence interval 1.15 to 7.85; 2 
studies, 339 women) were higher, but no differences 
were observed in other maternal outcomes (table 
1). Eighteen stillbirths (27 studies; 2837 offspring) 
and six neonatal deaths (26 studies; 1728 neonates) 
occurred among pregnant and recently pregnant 
women with covid-19, resulting in negligible risks 
(fig 3). Overall, 25% (95% confidence interval 14% 
to 37%; 17 studies, 1348 women) of neonates born to 
women with covid-19 were admitted to the neonatal 
unit (fig 3), with a higher risk of admission (odds ratio 
3.13, 95% confidence interval 2.05 to 4.78; 1 study, 
1121 neonates) than those born to mothers without 
the disease in one study with historical controls. No 
differences were observed for other perinatal outcomes. 
Appendix 9 provides the rates of covid-19 related 
and pregnancy related outcomes for the individual 
studies.
discussion
In this living systematic review, we found that one in 10 
pregnant or recently pregnant women who are attending 
or admitted to hospital for any reason are diagnosed as 
having suspected or confirmed covid-19, although the 
rates vary by sampling strategy. The covid-19 related 
symptoms of fever and myalgia manifest less often in 
pregnant and recently pregnant women than in non-
pregnant women of reproductive age. Whereas testing 
for SARS-CoV-2 in non-pregnant women is based 
on symptoms or contact history, testing in pregnant 
women is usually done when they are in hospital for 
reasons that might not be related to covid-19. Pregnant 
or recently pregnant women with covid-19 seem 
to be at increased risk of requiring admission to an 
intensive care unit or invasive ventilation. Increased 
maternal age, high body mass index, and pre-existing 
comorbidities might be associated with severe disease. 
Pregnant women with covid-19 are at increased risk 
of delivering preterm and their babies being admitted 
to the neonatal unit. But overall rates of spontaneous 
preterm births are not high. Stillbirth and neonatal 
death rates are low in women with suspected or 
confirmed covid-19. All comparative findings are 
based on small numbers of studies, despite the large 
sample sizes. Substantial heterogeneity was observed 
in the estimates for rates of clinical manifestations 
and outcomes, which varied by sampling frames, 
participant selection, and risk status of the 
participants.
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strengths and limitations of this review
In this unprecedented pandemic situation, where 
evidence is rapidly produced and published in various 
formats, our living systematic review underpinned by 
robust methods and continually updated at regular 
intervals is relevant for several reasons. Firstly, it 
addresses important research questions relevant 
to clinical decision making and policies. Secondly, 
uncertainties remain for key outcomes that require 
further evidence. Thirdly, the rapid turnover of 
evidence in various formats requires assessments of 
study quality and regular updating of the findings. 
Clinical manifestations
  Symptoms
    Fever
    Cough
    Dyspnoea
    Myalgia
    Ageusia
    Diarrhoea
  Laboratory findings
    Raised white cell count
    Lymphopaenia
    Thrombocytopaenia
    Abnormal liver function test results
    Raised procalcitonin level
    Raised C reactive protein level
  Radiological findings
    Ground glass appearance
    Any abnormality on computed tomography
Maternal and perinatal outcomes
  Covid related outcomes
    All cause mortality
    Admission to intensive care unit
    Severe covid-19
    Invasive ventilation
    ECMO
    Oxygen, cannula
    ARDS
    Pneumonia
    Cardiac, liver, renal failure
  Pregnancy related outcomes
    Preterm birth <37 weeks
    Spontaneous preterm birth
    PPROM <37 weeks
    Caesarean section
    Vaginal delivery
    Postpartum haemorrhage
Offspring outcomes
    Stillbirth
    Neonatal death
    Admission to neonatal unit
    Neonatal sepsis
    Abnormal Apgar score
    Fetal distress
(0.11-0.73)
(0.03-0.81)
(0.00-0.62)
(0.00-0.25)
(0.03-0.28)
(0.00-0.18)
(0.03-0.52)
(0.09-0.90)
(0.01-0.35)
(0.00-0.29)
(0.00-0.97)
(0.23-0.71)
(0.09-1.00)
(0.02-1.00)
(0.00-0.07)
(0.00-0.13)
(0.00-1.00)
(0.00-0.09)
(0.00-0.01)
(0.02-1.00)
(0.00-0.51)
(0.00-1.00)
(0.00-0.13)
(0.00-0.59)
(0.02-0.31)
(0.03-0.17)
(0.33-1.00)
(0.00-0.67)
(0.01-0.09)
(0.00-0.02)
(0.00-0.01)
(0.00-1.00)
(0.03-0.06)
(0.00-0.06)
(0.04-0.15)
Study Proportion
(95% CI)
Range
97.4 (0.00)
96.8 (0.00)
96.2 (0.00)
90.7 (0.00)
93.6 (0.00)
65.5 (0.00)
92.3 (0.00)
85.6 (0.00)
85.3 (0.00)
74.1 (0.00)
96.6 (0.00)
86.2 (0.00)
96.5 (0.00)
98.4 (0.00)
80.2 (0.00)
93.6 (0.00) 
95.5 (0.00) 
93.5 (0.00) 
0.0 (0.93) 
97.1 (0.00) 
98.7 (0.00)
97.9 (0.00) 
10.6 (0.35) 
71.5 (0.00) 
55.0 (0.02) 
0.0 (0.66)
91.3 (0.00)
91.4 (0.00) 
45.6 (0.14) 
0.0 (1.00) 
0.0 (1.00) 
94.9 (0.00) 
Not estimable
0.0 (0.64) 
0.0 (0.74) 
I2 (%)
(P value)
0.40 (0.31 to 0.49)
0.39 (0.31 to 0.47)
0.19 (0.13 to 0.26)
0.10 (0.05 to 0.17)
0.15 (0.00 to 0.41)
0.07 (0.05 to 0.09)
0.27 (0.09 to 0.51)
0.35 (0.26 to 0.45)
0.08 (0.02 to 0.18)
0.11 (0.05 to 0.18)
0.21 (0.00 to 0.59)
0.49 (0.36 to 0.63)
0.69 (0.41 to 0.91)
0.65 (0.46 to 0.82)
0.00 (0.00 to 0.01)
0.04 (0.02 to 0.07)
0.13 (0.06 to 0.21)
0.03 (0.01 to 0.05)
0.00 (0.00 to 0.01)
0.30 (0.14 to 0.48)
0.09 (0.00 to 0.33)
0.49 (0.35 to 0.63)
0.00 (0.00 to 0.01)
0.17 (0.13 to 0.21)
0.06 (0.03 to 0.09)
0.05 (0.03 to 0.08)
0.65 (0.57 to 0.73)
0.35 (0.27 to 0.43)
0.03 (0.00 to 0.08)
0.00 (0.00 to 0.00)
0.00 (0.00 to 0.00)
0.25 (0.14 to 0.37)
0.04 (0.00 to 0.12)
0.01 (0.00 to 0.02)
0.08 (0.05 to 0.12)
Proportion
(95% CI)
29
28
22
9
3
17
6
15
7
9
5
7
10
20
26
17
21
13
9
13
6
23
7
30
10
8
28
27
5
27
26
17
2
14
7
Studies
2733/8328
3432/8317
1928/8159
1411/6078
24/310
659/7525
50/251
262/780
36/428
51/491
60/261
174/426
246/387
599/1968
73/11 580
323/10 901
417/2271
155/10 713
16/1935
243/1281
270/1006
729/2577
7/737
386/1872
56/870
28/436
1060/1933
856/1916
13/250
18/2837
6/1728
368/1348
2/51
11/500
25/293
Events/
No in group
0 0.2 0.4 0.6 0.8 1.0
Fig 3 | rates of clinical manifestations of coronavirus disease (covid-19) in pregnant women and recently pregnant women with suspected or 
confirmed covid-19 and associated maternal and perinatal outcomes. ecmO=extracorporeal membrane oxygenation; arDs=acute respiratory 
distress syndrome; PPrOm=preterm premature rupture of membranes
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Finally, our living systematic review will produce a 
strong evidence base for living guidelines on covid-19 
and pregnancy.
We undertook a comprehensive search and coordi-
nated our efforts with key organisations and research 
groups, such as WHO, the Cochrane Centre, and EPPI-
Centre. To minimise risk of bias we restricted our meta-
analysis to cohort studies, and we reported the quality 
of the included studies. By contacting the authors 
and obtaining reports not published in PubMed, we 
minimised the risk of missing relevant studies. Our 
systematic review has a large sample size and it is 
continuously increasing. Our living meta-analyses 
framework will enable us to rapidly update the findings 
as new data emerge. We undertook extensive work to 
ensure that duplicate data are not included. Our various 
comparative analyses allowed us to comprehensively 
assess the association between pregnancy and 
covid-19 related outcomes, covid-19 and pregnancy 
outcomes, risk factors for SARS-CoV-2 infection, and 
complications. Our review helps to understand the 
variations in estimates through sensitivity analyses by 
sampling strategies, population characteristics, and 
risk factors, and it provides confidence in the rates of 
reported outcomes.
Our systematic review also has limitations. The 
primary studies used varied sampling frames to 
identify women with covid-19, comprised women 
with suspected and confirmed covid-19, and primarily 
reported on pregnant women who required visits to 
hospital, including for childbirth, thereby affecting 
the generalisability of the estimates. Although our 
Any symptom
  Cheng 2020
  Wei 2020
  Wang 2020
  Ellington 2020
Subtotal: I2=80.3%
Fever
  Liu 2020
  Yin 2020
  Cheng 2020
  Wang 2020
  Ellington 2020
Subtotal: I2=73.9%
Cough
  Liu 2020
  Yin 2020
  Cheng 2020
  Wang 2020
  Ellington 2020
Subtotal: I2=67.6%
Dyspnoea
  Liu 2020
  Yin 2020
  Cheng 2020
  Wang 2020
  Ellington 2020
Subtotal: I2=36.0%
Myalgia
  Yin 2020
  Cheng 2020
  Ellington 2020
Subtotal: I2=73.9%
0.16 (0.05 to 0.54)
0.62 (0.08 to 4.92)
0.03 (0.00 to 0.56)
1.07 (0.91 to 1.26)
0.33 (0.08 to 1.41)
0.22 (0.06 to 0.85)
0.20 (0.06 to 0.66)
0.59 (0.26 to 1.37)
0.29 (0.11 to 0.77)
0.87 (0.82 to 0.93)
0.43 (0.22 to 0.85)
0.55 (0.15 to 2.05)
1.11 (0.42 to 2.93)
0.55 (0.24 to 1.27)
0.20 (0.06 to 0.62)
1.10 (1.04 to 1.17)
0.67 (0.37 to 1.23)
0.90 (0.05 to 15.47)
1.00 (0.33 to 3.03)
0.32 (0.11 to 0.92)
0.39 (0.04 to 3.72)
1.12 (1.05 to 1.20)
0.82 (0.47 to 1.43)
0.52 (0.12 to 2.27)
0.30 (0.04 to 2.50)
0.48 (0.45 to 0.51)
0.48 (0.45 to 0.51)
Symptoms Odds ratio
(95% CI)
22/31
15/17
22/30
5199/5355
5258/5433
8/21
17/31
15/31
11/30
1190/5355
1241/5468
6/21
15/31
14/31
5/30
1799/5355
1839/5468
1/21
8/31
5/31
1/27
1045/5355
1060/5465
3/31
1/31
1323/8207
1327/8269
No of pregnant
women with covid-19/
No in group
75/80
24/26
42/42
72 549/74 877
72 690/75 025
14/19
30/35
49/80
28/42
18 474/74 877
18 595/75 053
8/19
16/35
48/80
21/42
23 554/74 877
23 647/75 053
1/19
9/35
30/80
4/45
13 292/74 877
13 336/75 056
6/35
8/80
20 726/72 025
20 740/72 140
No of non-pregnant
women with covid-19/
No in group
0.01
Note: Weights are from random effects analysis
0.25 0.5 2 101 100
Odds ratio
(95% CI)
Fig 4 | clinical manifestations of coronavirus disease (covid-19) in pregnant and recently pregnant women compared with non-pregnant women of 
reproductive age with covid-19
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sensitivity analyses aimed to tackle some of these 
problems, the numbers and sample sizes of the 
individual studies were too small to identify differences 
between the subgroups. The timing of assessment of 
the clinical manifestations of disease was generally 
not available. The definitions of symptoms, tests, 
and outcomes were heterogeneous. Furthermore, 
poor reporting of the criteria for caesarean section, 
admissions to the neonatal unit, and the causes 
of preterm birth, made it difficult to disentangle 
iatrogenic effect from the true impact of the disease. 
There is a paucity of comparative data to assess the risk 
of severe disease in pregnant women compared with 
non-pregnant women in similarly aged groups, and 
to compare pregnancy outcomes in women with and 
without covid-19. Not many studies reported outcomes 
by trimester for symptom onset, making it difficult 
to assess the rates of miscarriage and postpartum 
complications. For some outcomes, the findings were 
influenced by a single large study.26 Many studies 
had to be excluded as we could not rule out potential 
overlap in the study populations.
comparison with existing evidence
Alongside the spread of the pandemic, a shift has 
occurred in the types of studies published, with initial 
studies involving pregnant women from epidemic regions 
in China, followed by reports of large regional and 
national datasets from the US, UK, Netherlands, Spain, 
and, more recently, Latin American countries. The study 
design has also changed from initial small case series 
and case reports to large observational data, with recent 
studies also providing comparative data. The prevalence 
of covid-19 varied widely between studies, particularly 
when sampling was done based on symptoms or history 
of contact, highlighting the variations in criteria for 
testing. Moreover, the findings only relate to those women 
attending hospital for any reason. The true prevalence 
of covid-19 in pregnancy is likely to be lower when all 
pregnant women are included.
In the recent cohort study of all individuals admitted 
with covid-19 in the UK, the cluster of respiratory 
symptoms of cough, fever, and breathlessness were 
observed in more than two thirds of individuals,77 
similar to reported rates in the US and China.78-80 But 
in our review, fewer pregnant and recently pregnant 
women with covid-19 manifested these symptoms 
than the non-pregnant population, indicating possi-
ble high rates of asymptomatic presentation in this 
population. This is likely because of the strategy of 
universal screening for covid-19 in pregnancy and 
the low thresholds for testing than in non-pregnancy. 
Despite the possibility of the above strategies detecting 
pregnant women with mild disease, we observed an 
increase in admissions to the intensive care unit and 
need for invasive ventilation compared with non-
pregnant women of reproductive age with covid-19. 
The findings were mainly influenced by the recent 
large Centers for Disease Control and Prevention report 
from the US.26 Pregnancy status was not ascertained 
in a large proportion of women of reproductive age 
in the CDC report that could affect the estimates. 
Furthermore, the outcomes for which the data were 
missing were considered to be absent in the report, 
thereby incurring bias. The pooled estimates for severe 
covid-19 and admission to an intensive care unit were, 
however, still relatively high in the non-comparative 
data, indicative of a potential high risk in pregnancy. 
This is supported by the recent analysis in a Swedish 
study suggesting a high risk of admission to an 
intensive care unit and invasive ventilation in pregnant 
women than non-pregnant women.81
table 1 | Outcomes in pregnant and recently pregnant women with coronavirus disease 2019 (covid-19)
Outcomes no of studies
women (no with event/no in group (%))
Odds ratio (95% ci) i2 (%)Pregnant women with covid-19 comparison group
comparison group: non-pregnant women of reproductive age with covid-19
All cause mortality 4 16/8282 (0.2) 208/83 327 (0.2) 0.81 (0.49 to 1.33) 0
ICU admission 4 121/8276 (1.5) 758/83 330 (0.9) 1.62 (1.33 to 1.96) 0
Invasive ventilation 4 43/8276 (0.5) 226/83 330 (0.3) 1.88 (1.36 to 2.60) 0
ECMO 1 0/31 (0) 0/80 (0) 2.56 (0.05 to 131.60) NE
Oxygen through nasal cannula 2 8/48 (16.7) 49/106 (46.2) 0.21 (0.04 to 1.13) 65.7
ARDS 1 0/17 (0) 0/26 (0) 1.51 (0.03 to 79.93) NE
Major organ failure 1 0/17 (0) 0/26 (0) 1.51 (0.03 to 79.93) NE
comparison group: pregnant women without covid-19
Maternal outcomes:
 All cause mortality 1* 5/427 (1.2) 0/694 (0) 18.08 (1.00 to 327.83) NE
 ICU admission 1* 40/427 (9.4) 1/694 (0.1) 71.63 (9.81 to 523.06) NE
 Preterm birth <37 weeks 2 7/44 (15.9) 18/295 (6.1) 3.01 (1.16 to 7.85) 0.9
 Caesarean section 3* 184/491 (37.5) 577/1676 (34.4) 2.02 (0.67 to 6.10) 87.5
Perinatal outcomes:
 Stillbirth 1* 3/427 (0.7) 2/694 (0.3) 2.45 (0.41 to 14.71) NE
 Neonatal death 1* 2/427 (0.5) 1/694 (0.1) 3.26 (0.30 to 36.07) NE
 Admission to neonatal unit 1* 64/427 (15.0) 37/694 (5.3) 3.13 (2.05 to 4.79) NE
 Abnormal Apgar score at 5 minutes 1 0/30 (0) 12/740 (1.6) 0.96 (0.06 to 16.51) NE
 Fetal distress 1 3/34 (8.8) 12/242 (5.0) 1.86 (0.50 to 6.94) NE
ICU=intensive care unit; ECMO=extracorporeal membrane oxygenation; ARDS=acute respiratory distress syndrome; NE=not estimable.
The denominator is number of pregnancies for all outcomes.
*Historical comparative cohort in UK Obstetric Surveillance System study.
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Age*
  Kayem 2020
  Martinez-Perez 2020
  Khoury 2020
  Chen 2020 (continuous age)
Subtotal: I2=9%
Body mass index
  Kayem 2020
  Martinez-Perez 2020
  Khoury 2020
  Wu 2020
Subtotal: I2=0%
Multiparity
  Chen 2020
  Savasi 2020
  Martinez-Perez 2020
Subtotal: I2=0%
Third trimester
  Yan 2020
  Andrikopoulou 2020
Subtotal: I2=0%
Non-white
  Savasi 2020
  Khoury 2020
Subtotal: I2=73%
Any comorbidity
  Savasi 2020
  Martinez-Perez 2020
Subtotal: I2=0%
Chronic hypertension
  Kayem 2020
  Khoury 2020
Subtotal: I2=0%
Pre-existing diabetes
  Kayem 2020
  Khoury 2020
Subtotal: I2=12%
Pre-eclampsia
  Yan 2020
  Martinez-Perez 2020
Subtotal: I2=0%
Gestational diabetes
  Andrikopoulou 2020
  Kayem 2020
  Martinez-Perez 2020
  Yan 2020
Subtotal: I2=0%
2.24 (1.50 to 3.35)
1.00 (0.13 to 7.46)
1.19 (0.65 to 2.18)
1.87 (0.55 to 6.42)
1.78 (1.25 to 2.55)
2.39 (1.56 to 3.66)
1.11 (0.11 to 11.35)
2.51 (1.31 to 4.81)
Excluded
2.38 (1.67 to 3.39)
1.39 (0.35 to 5.47)
0.82 (0.25 to 2.66)
1.42 (0.14 to 14.29)
1.07 (0.46 to 2.46)
0.64 (0.07 to 5.76)
0.59 (0.26 to 1.32)
0.59 (0.28 to 1.27)
1.88 (0.57 to 6.17)
0.45 (0.19 to 1.06)
0.86 (0.21 to 3.50)
1.88 (0.57 to 6.17)
0.71 (0.07 to 7.14)
1.53 (0.53 to 4.41)
2.51 (0.95 to 6.62)
1.78 (0.90 to 3.51)
2.00 (1.14 to 3.48)
3.98 (1.37 to 11.57)
1.98 (0.96 to 4.08)
2.51 (1.31 to 4.80)
5.00 (0.46 to 54.51)
8.33 (0.66 to 105.71)
6.35 (1.11 to 36.22)
0.60 (0.07 to 5.13)
1.23 (0.69 to 2.21)
5.74 (0.20 to 161.79)
Excluded
1.23 (0.70 to 2.14)
Risk factors Odds ratio
(95% CI)
59/128
2/4
22/75
n/9
83/216
46/128
1/4
43/62
0/0
90/194
5/9
8/14
3/4
16/27
7/8
22/34
29/42
6/14
54/65
60/79
6/14
1/4
7/18
7/128
18/75
25/203
7/128
16/75
23/203
1/8
1/4
2/12
1/34
17/128
0/4
0/0
18/166
No of pregnant women
with risk factor and severe
covid-19/No in group
135/489
39/78
43/166
n/109
219/842
93/489
18/78
55/116
0/13
166/696
46/97
39/63
53/78
138/238
99/108
94/124
193/232
18/63
143/156
161/219
18/63
25/78
43/141
11/489
25/166
36/655
7/489
20/166
27/655
3/108
3/78
6/186
6/124
54/489
1/78
9/116
70/807
No of pregnant women
with risk factor without
severe covid-19/No in group
Note: Weights are from random effects analysis
0.01 0.25 0.5 2 101 100
Odds ratio
(95% CI)
Fig 5 | risk factors associated with severe coronavirus disease 2019 (covid-19) in pregnant and recently pregnant women. symptom based 
screening: savasi v, Kayem g; nHcc (national Health commission china). criteria based screening: chen, wu, yan. all other studies used universal 
screening. cut-off for age is 35 years or more, and for body mass index is 30 or more. *includes one study with continuous measurement of risk 
factor
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Similar to the general population, high body mass 
index and pre-existing comorbidity seemed to be risk 
factors for severity of covid-19 in pregnancy, including 
admission to an intensive care unit and invasive 
ventilation.77 Complications related to covid-19 did 
not seem to be increased in women presenting in the 
third trimester or in multiparous women—but existing 
sample sizes are not large. Both chronic hypertension 
and pre-existing diabetes were associated with 
maternal death in pregnant women with covid-19, 
which are known risk factors in the general population. 
But it is not known if covid-19 was the direct cause of 
death for these women, and the numbers of studies 
are small. We observed an increase in rates of preterm 
birth in pregnant women with covid-19 compared 
with those without the disease. These preterm births 
could be medically indicated, as the overall rates of 
spontaneous preterm births in pregnant women with 
covid-19 was broadly similar to those observed in the 
pre-pandemic period. Although more than 60% of 
pregnant women underwent caesarean section in the 
non-comparative studies, we did not find a statistically 
significant difference in comparative studies of 
pregnant women with and without covid-19. The 
precision of the estimates is expected to improve with 
the publication of more data in the future. The overall 
table 2 | maternal characteristics associated with severe coronavirus disease 2019 (covid-19) and all cause death in 
pregnant and recently pregnant women with a diagnosis of covid-19
maternal risk factors and 
outcomes
no of  
studies
total no  
of women
Pregnant women (no with risk factor/no 
in group (%))
Odds ratio (95% ci) i2 (%)with outcome without outcome
Age ≥35 years:
 Severe disease 4 1058 216* 842* 1.78 (1.25 to 2.55) 9
 ICU admission 2 260 8/87 (9.2) 8/173 (4.6) 2.44 (0.43 to 14.01) 63
 Invasive ventilation 1 178 3/65 (4.6) 2/113 (1.8) 2.69 (0.44 to 16.51) NE
 Maternal death 1 288 20/154 (13.0) 16/134 (11.9) 1.10 (0.55 to 2.22) NE
Multiparity:
 Severe disease 3 265 16/154 (10.4) 11/111 (9.9) 1.07 (0.46 to 2.46) 0
 ICU admission 1 42 4/22 (18.2) 4/20 (20.0) 0.89 (0.19 to 4.15) NE
Body mass index ≥30:
 Severe disease 3 877 90/256 (35.2) 104/621 (16.7) 2.38 (1.67 to 3.39) 0
 ICU admission 1 142 3/22 (13.6) 4/120 (3.3) 4.58 (0.95 to 22.09) NE
 Invasive ventilation 1 135 5/21 (23.8) 6/114 (5.3) 5.63 (1.54 to 20.59) NE
 Maternal death 2 596 6/62 (9.7) 37/534 (6.9) 2.57 (0.97 to 6.82) 0
Non-white ethnicity:
 Severe disease 2 298 60/221 (27.1) 19/77 (24.7) 0.86 (0.21 to 3.50) 73
 ICU admission 1 42 5/20 (25.0) 3/22 (13.6) 2.11 (0.43 to 10.28) NE
 Maternal death 2 596 31/220 (14.1) 12/376 (3.2) 2.40 (0.94 to 6.11) 0
Any comorbidity:
 Severe disease 2 159 7/50 (14.0) 11/109 (10.1) 1.53 (0.53 to 4.41) 0
 ICU admission 2 320 4/37 (10.8) 11/283 (3.9) 4.21 (1.06 to 16.72) 0
 Invasive ventilation 2 313 6/36 (16.7) 10/277 (3.6) 4.48 (1.40 to 14.37) 0
Chronic hypertension:
 Severe disease 2 858 25/61 (41.0) 178/797 (22.3) 2.0 (1.14 to 3.48) 0
 ICU admission 1 141 2/5 (40.0) 5/136 (3.7) 17.47 (2.37 to 129.02) NE
 Invasive ventilation 1 134 4/5 (80.0) 7/129 (5.4) 69.71 (6.85 to 709.34) NE
 Maternal death 2 596 5/29 (17.2) 38/567 (6.7) 3.38 (1.17 to 9.75) 0
Pre-existing diabetes:
 Severe disease 2 858 23/50 (46.0) 180/808 (22.3) 2.51 (1.31 to 4.80) 12
 ICU admission 2 181 1/7 (14.3) 14/174 (8.0) 2.88 (0.44 to 18.96) 0
 Invasive ventilation 1 132 1/6 (16.7) 9/126 (7.1) 2.60 (0.27 to 24.71) NE
 Maternal death 2 596 10/52 (19.2) 33/544 (6.1) 6.63 (0.27 to 161.45) 91
Asthma:
 Severe disease 3 857 17/61 (27.9) 149/796 (18.7) 1.86 (0.88 to 3.93) 22
 Maternal death 2 596 3/22 (13.6) 40/574 (7.0) 2.04 (0.61 to 6.85) 0
Smoking:
 Severe disease 3 776 5/23 (21.7) 141/753 (18.7) 1.67 (0.64 to 4.40) 0
 ICU admission 1 42 1/2 (50.0) 7/40 (17.5) 4.71 (0.26 to 84.77) NE
 Maternal death 1 308 0/10 (0) 7/298 (2.3) 1.85 (0.10 to 34.60) NE
Gestation ≥28 weeks:
 Severe disease 2 274 29/222 (13.1) 13/52 (25.0) 0.59 (0.28 to 1.27) 0
 Maternal death 1 273 22/190 (11.6) 12/83 (14.5) 0.78 (0.36 to 1.65) NE
Gestational diabetes:
 Severe disease 4 973 18/88 (20.5) 148/885 (16.7) 1.23 (0.70 to 2.14) 0
Pre-eclampsia:
 Severe disease 2 198 2/8 (25.0) 10/190 (5.3) 6.36 (1.12 to 36.22) 0
 ICU admission 1 42 6/6 (100.0) 2/36 (5.6) 179.40 (7.69 to 4186.05) NE
ICU=intensive care unit; NE=not estimable.
*Includes one or more studies with continuous measurement of risk factor.
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rates of stillbirths and neonatal deaths do not seem to 
be higher than the background rates. The indications 
for admissions to the neonatal unit, observed in 
about a quarter of neonates delivered to mothers with 
covid-19, have not been reported. Local policies on 
observation and quarantine of infants with exposure 
to SARS-CoV-2 might have influenced these rates.
relevance for clinical practice and research
Based on existing data, healthcare professionals 
should be aware that pregnant and recently pregnant 
women with covid-19 might manifest fewer symptoms 
than the general population, with the overall pattern 
similar to that of the general population. Emerging 
comparative data indicate the potential for an increase 
in the rates of admission to intensive care units and 
invasive ventilation in pregnant women compared 
with non-pregnant women. Mothers with pre-existing 
comorbidities will need to be considered as a high risk 
group for covid-19, along with those who are obese and 
of greater maternal age. Clinicians will need to balance 
the need for regular multidisciplinary antenatal care 
to manage women with pre-existing comorbidities 
against unnecessary exposure to the virus, through 
virtual clinic appointments when possible. Pregnant 
women with covid-19 before term gestation might 
need to be managed in a unit with facilities to care for 
preterm neonates.
Further data are needed to assess robustly if preg-
nancy related maternal and neonatal complications are 
increased in women with covid-19 than those without 
the disease. Similarly, the association between other 
risk factors such as ethnicity and pregnancy specific 
risk factors such as pre-eclampsia and gestational 
diabetes on both covid-19 related and pregnancy 
related outcomes needs evaluation. Pre-eclampsia 
was reported to be associated with severe covid-19 
in small studies, but it requires further assessment 
as the clinical presentation of severe pre-eclampsia 
could mimic worsening covid-19.82 Robust collection 
of maternal data by trimester of exposure, including 
the periconception period, is required to determine the 
effects of covid-19 on early pregnancy outcomes, fetal 
growth, and risk of stillbirth.
Systematic reviews are considered to be the highest 
quality evidence informing guidelines, and poor 
quality reviews will have a direct impact on clinical 
care. Despite the urgent need for evidence on the 
impact of covid-19 in pregnant women, systematic 
reviews and meta-analyses still need to adhere to 
the reporting guidelines on search criteria, quality 
assessment, and analysis. This is particularly impor-
tant as large numbers of non-peer reviewed scientific 
papers and reports are currently available in the public 
domain in multiple versions. Primary studies need to 
explicitly state if duplicate data have been included 
to avoid double counting of participants in evidence 
synthesis. Individual participant data meta-analysis 
of the emerging cohorts is critical to assess both 
differential presentation and outcomes by underlying 
risk factors, and to determine the differential effects 
of interventions to reduce the rates of complications. 
With the establishment of several national and global 
prospective cohorts, we expect the sample size of 
our meta-analysis to increase further in the coming 
months. Our living systematic review and meta-
analysis with its regular search and analyses updates 
is ideally placed to assess the impact of new findings 
on the rapidly growing evidence base.
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